Market overview
The global next generation sequencing market is worth USD 16.4 bn in 2026 and is forecast to reach USD 55.6 bn by 2036, growing at a 13.0% CAGR. United States is the largest country market and Consumables and reagents is the largest by product segment.
| Scope | Sequencers, reagents and consumables, and sequencing services used to read DNA and RNA at scale for research, clinical testing and agriculture. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 14.5 bn |
| Value 2026 | USD 16.4 bn |
| Value 2036 | USD 55.6 bn |
| CAGR 2026-2036 | 13.0% |
| Volume 2026 | 29.1 million samples |
| Volume 2036 | 134 million samples |
| Average price 2026 | USD 563 per sample |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Next Generation Sequencing market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 16.4 bn |
| 2027 | USD 18.5 bn |
| 2028 | USD 20.9 bn |
| 2029 | USD 23.6 bn |
| 2030 | USD 26.7 bn |
| 2031 | USD 30.2 bn |
| 2032 | USD 34.1 bn |
| 2033 | USD 38.5 bn |
| 2034 | USD 43.6 bn |
| 2035 | USD 49.2 bn |
| 2036 | USD 55.6 bn |
Next Generation Sequencing market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Consumables and reagents | 62.0% | 63.8% | USD 10.2 bn | 13.3% |
| Instruments | 16.0% | 11.5% | USD 2.6 bn | 9.3% |
| Services | 22.0% | 24.7% | USD 3.6 bn | 14.3% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Clinical oncology | 30.0% | 32.7% | USD 4.9 bn | 14.0% |
| Reproductive and genetic health | 20.0% | 19.9% | USD 3.3 bn | 13.0% |
| Research and drug discovery | 34.0% | 28.4% | USD 5.6 bn | 11.0% |
| Infectious disease and other | 16.0% | 19.0% | USD 2.6 bn | 15.0% |
By sequencing technology
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Short-read sequencing | 62.0% | 54.0% | USD 10.2 bn | 11.4% |
| Long-read sequencing | 24.0% | 32.0% | USD 3.9 bn | 16.3% |
| Targeted and nanopore | 14.0% | 14.0% | USD 2.3 bn | 13.0% |
By workflow
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Sample preparation | 22.0% | 20.0% | USD 3.6 bn | 11.9% |
| Sequencing | 38.0% | 35.0% | USD 6.2 bn | 12.1% |
| Data analysis | 40.0% | 45.0% | USD 6.6 bn | 14.3% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Academic and research | 34.0% | 30.0% | USD 5.6 bn | 11.6% |
| Clinical laboratories | 30.0% | 34.0% | USD 4.9 bn | 14.4% |
| Pharma and biotech | 24.0% | 24.0% | USD 3.9 bn | 13.0% |
| Hospitals | 12.0% | 12.0% | USD 2.0 bn | 13.0% |
Top 25 countries for next generation sequencing by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 86.5% of 2026 revenue and the 25 countries below together hold 96.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 6.9 bn | 42.0% | USD 21.8 bn | 12.2% |
| 2 | China | USD 2.3 bn | 14.0% | USD 9.5 bn | 15.2% |
| 3 | United Kingdom | USD 983 mn | 6.0% | USD 3.1 bn | 12.2% |
| 4 | Germany | USD 819 mn | 5.0% | USD 2.6 bn | 12.3% |
| 5 | Japan | USD 819 mn | 5.0% | USD 2.4 bn | 11.3% |
| 6 | France | USD 573 mn | 3.5% | USD 1.8 bn | 12.3% |
| 7 | Canada | USD 492 mn | 3.0% | USD 1.6 bn | 12.2% |
| 8 | South Korea | USD 492 mn | 3.0% | USD 1.8 bn | 14.1% |
| 9 | Australia | USD 410 mn | 2.5% | USD 1.4 bn | 13.0% |
| 10 | India | USD 410 mn | 2.5% | USD 2.0 bn | 17.2% |
| 11 | Spain | USD 297 mn | 1.8% | USD 1.0 bn | 13.2% |
| 12 | Italy | USD 242 mn | 1.5% | USD 840 mn | 13.2% |
| 13 | Netherlands | USD 200 mn | 1.2% | USD 690 mn | 13.2% |
| 14 | Brazil | USD 164 mn | 1.0% | USD 567 mn | 13.2% |
| 15 | Switzerland | USD 134 mn | 0.8% | USD 467 mn | 13.3% |
| 16 | Singapore | USD 110 mn | 0.7% | USD 378 mn | 13.2% |
| 17 | Taiwan | USD 97 mn | 0.6% | USD 339 mn | 13.4% |
| 18 | Sweden | USD 82 mn | 0.5% | USD 289 mn | 13.4% |
| 19 | Denmark | USD 62 mn | 0.4% | USD 217 mn | 13.3% |
| 20 | Israel | USD 54 mn | 0.3% | USD 184 mn | 13.0% |
| 21 | Belgium | USD 46 mn | 0.3% | USD 156 mn | 13.0% |
| 22 | Mexico | USD 38 mn | 0.2% | USD 128 mn | 13.0% |
| 23 | Saudi Arabia | USD 28 mn | 0.2% | USD 95 mn | 13.0% |
| 24 | Poland | USD 23 mn | 0.1% | USD 78 mn | 13.0% |
| 25 | Turkey | USD 18 mn | 0.1% | USD 61 mn | 13.0% |
| Rest of world | USD 618 mn | 3.8% | USD 2.1 bn | 13.0% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Illumina
- Thermo Fisher Scientific
- MGI Tech
- Pacific Biosciences
- Oxford Nanopore Technologies
- Agilent Technologies
Group 2: Regional and specialist players
- Roche
- Element Biosciences
- Ultima Genomics
- QIAGEN
- Novogene
- BGI Genomics
- Azenta Life Sciences
- Eurofins Genomics
- Twist Bioscience
Group 3: Emerging and niche players
- Singular Genomics
- Macrogen
- Psomagen
- GeneMind Biosciences
- Berry Genomics
- CD Genomics
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the next generation sequencing market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 13.0% is calculated from the resulting values.
The market is divided by product, by application, by sequencing technology, by workflow, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the next generation sequencing market?
The global next generation sequencing market is estimated at USD 14.5 bn in 2025 and USD 16.4 bn in 2026.
How fast will the next generation sequencing market grow?
It is forecast to reach USD 55.6 bn by 2036, a compound annual growth rate of 13.0% from 2026, an increase of USD 39.2 bn.
Which country is the largest market for next generation sequencing?
United States is the largest market by revenue at USD 6.9 bn in 2026, 42.0% of the global total. The three largest countries together hold 62.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 17.2% a year from 2026 to 2036.
Which next generation sequencing segment is largest?
In the by product split, Consumables and reagents is the largest segment with 62.0% of 2026 revenue.
Who are the leading next generation sequencing companies?
Global leaders include Illumina, Thermo Fisher Scientific, MGI Tech, Pacific Biosciences.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Antibody Drug ConjugatesUSD 16.5 bn · 14.5% CAGR
- Downstream ProcessingUSD 16.6 bn · 10.5% CAGR
- Rare Cardiovascular Disease TherapeuticsUSD 16.1 bn · 9.0% CAGR
- Insulin DeliveryUSD 16.8 bn · 8.0% CAGR
- Pharmaceutical FiltrationUSD 15.8 bn · 9.0% CAGR
- SpectroscopyUSD 15.4 bn · 6.0% CAGR
- Fill FinishUSD 17.6 bn · 9.0% CAGR
- Surgical RoboticsUSD 17.7 bn · 14.0% CAGR
← New Approach Methodologies Nonclinical Testing Nuclear Medicine →